Forsteo ® (teriparatide)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).

What adverse reactions are associated with abrupt discontinuation of Forsteo® (teriparatide) ?

Eli Lilly and Company has not identified any safety concerns, including adverse reactions or side effects, associated with abrupt discontinuation of teriparatide therapy for the treatment of osteoporosis.

UK_cFAQ_TER002_AE_ABRUPTLY_STOPPING
UK_cFAQ_TER002_AE_ABRUPTLY_STOPPING
en-GB

Adverse events following abrupt stopping of treatment

Eli Lilly and Company (Lilly) has not identified any safety concerns, including adverse reactions or side effects, associated with temporary interruption or abrupt withdrawal of teriparatide therapy for the treatment of osteoporosis during our clinical studies or follow-up analyses.1-6

The recommended treatment time is 24 months.7

References

1Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434-1441. http://dx.doi.org/10.1056/nejm200105103441904

2Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003;18(1):9-17. https://dx.doi.org/10.1359/jbmr.2003.18.1.9

3Lindsay R, Scheele WH, Neer R, et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med. 2004;164(18):2024-2030. http://dx.doi.org/10.1001/archinte.164.18.2024

4Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007;357(20):2028-2039. http://dx.doi.org/10.1056/NEJMoa071408

5Silverman S, Miller P, Sebba A, et al. The direct assessment of nonvertebral fractures in community experience (DANCE) study: 2-year nonvertebral fragility fracture results. Osteoporos Int. 2013;24(8):2309-2317. https://dx.doi.org/10.1007/s00198-013-2284-y

6Saag KG, Zanchetta JR, Devogelaer JP, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-sixmonth results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009;60(11):3346-3355. https://doi.org/10.1002/art.24879

7Forsteo [package leaflet]. Eli Lilly Nederland B.V., The Netherlands.

Date of Last Review: 01 September 2022


Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request